Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study

Abstract Chronic graft-versus-host disease (cGVHD) is a major complication for long-term survivors after hematopoietic cell transplantation (HCT). Bronchiolitis obliterans syndrome (BOS) is the crucial manifestation of lung cGVHD. Ruxolitinib has been approved by the Food and Drug Administration (FD...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yuqing Tu, Lingyi Yang, Yaxin Cheng, Yanming Zhang, Yinghao Lu, Shushu Xu, Xiaoli Li, Mimi Xu, Mengqi Xiang, Yi Fan, Yuhua Ru, Yang Xu, Feng Chen, Xiaojin Wu, Yulian Zheng, Fei Li, Yue Han, Xiaowen Tang, Huiying Qiu, Miao Miao, Ye Zhao, Xiaoyu Zhu, Depei Wu, Jia Chen
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer 2025-11-01
Col·lecció:	Annals of Hematology
Matèries:	Ruxolitinib Bronchiolitis obliterans syndrome Chronic graft-versus-host disease Allogeneic hematopoietic cell transplantation
Accés en línia:	https://doi.org/10.1007/s00277-025-06726-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!